Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

• Status: Completed
• Trial end date: 2016-07-30
• Target enrollment: 0
• Participant gender: All

Summary

This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to proactive therapy especially in real-life rural settings where public transportations are not readily available.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Regeneron Pharmaceuticals
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• [Patients]

• Female and male out-patients diagnosed with wAMD.

• Patients who are accompanied by his/her caregiver(s).

• Patients who have been receiving anti-VEGF therapy with proactive regimen for 12 months or more at the participating site.

• Providing informed consent for the participation in this study.

• [Caregivers]

• Providing informed consent for the participation in this study.

• Capable of understanding and completing the questionnaires without any help from others

Exclusion Criteria:

• [Patients]

• Presence of a disease or a condition more disabling than wAMD in term of caregiving.

• Presence of intractable neurologic disease, physical handicap, mental handicap, or any condition that rendered them unable to walk independently.

• Intraocular surgery for other eye diseases after the start of wAMD therapy.

• [Caregivers]

• Professional carers